Las Vegas Spine & Disc

Regenerative Approaches to Disc Herniation: What PRP, BMAC, and Non-Surgical Decompression Research Shows in 2026

Growing clinical evidence suggests that regenerative therapies and computer-controlled decompression may help disc herniation patients avoid surgery while producing measurable improvements on imaging, giving patients and providers a clearer picture of what non-surgical care can and cannot do.

Las Vegas Spine & Disc · July 12, 2026 · 7 min read

Key takeaways

  • A 2025 case series in the Journal of Contemporary Chiropractic found that non-surgical spinal decompression produced significant pain and disability improvements, with 75% of participants reporting positive subjective recovery and MRI imaging confirming increased disc height.
  • PRP (platelet-rich plasma), BMAC (bone marrow aspirate concentrate), and LIPUS (low-intensity pulsed ultrasound) are the subject of multiple clinical trials exploring how biological agents may support disc tissue regeneration.
  • The RESTORE study (NCT06525896), a University of South Florida clinical trial examining non-surgical decompression with radiographic evaluation, launched in January 2025 with a primary completion date estimated for August 2026.
  • Current evidence supports non-surgical approaches as genuinely promising for many disc herniation patients, though individual suitability varies and these findings do not substitute for a thorough clinical evaluation.
DISC RECOVERY
Non-Surgical Disc Treatment Research: Key Data Points for 2026
75%
Positive subjective recovery rate in 2025 non-surgical decompression case series (Journal of Contemporary Chiropractic)
3
Regenerative biological approaches with current clinical trial evidence for disc herniation: PRP, BMAC, and LIPUS
Aug 2026
Estimated primary completion date for the RESTORE study (NCT06525896), University of South Florida radiographic decompression trial
MRI-confirmed
Disc height increase documented in 2025 non-surgical decompression case series via objective imaging measurement

Sources: Journal of Contemporary Chiropractic (parker.edu, 2025 case series); Journal of Clinical Medicine MDPI review on non-surgical and regenerative therapies for lumbar disc herniation (mdpi.com, 2024); ClinicalTrials.gov NCT06525896.

Why Disc Herniation Research Is Evolving Quickly

Lumbar disc herniation affects a significant portion of adults seeking care for back and leg pain, and for decades the primary clinical debate centered on two options: conservative management through rest and physical therapy, or surgery. That binary has been shifting steadily. The past several years have produced a more nuanced picture in which a range of non-surgical interventions, some technology-driven and others biologically based, are generating reproducible clinical outcomes that deserve serious attention from patients and providers alike.

This shift matters for people who are living with disc-related pain and who have assumed, or been told, that surgery is their eventual destination. The research accumulating in 2025 and 2026 suggests that for many patients, non-surgical approaches may produce meaningful improvements in pain, function, and even the structural characteristics of the affected disc, without the recovery period and risk profile that surgery carries. Understanding what the evidence actually supports, and where its limits lie, is useful for anyone navigating these decisions.

What Non-Surgical Decompression Studies Are Finding

Non-surgical spinal decompression uses computer-controlled traction to apply targeted distraction forces to affected spinal segments. The goal is to create a negative intradiscal pressure that may draw herniated disc material back toward the center and promote nutrient exchange in a structure that has limited direct blood supply. The therapy has been used for years, but recent research is adding more rigorous data to what was previously a clinical field that relied heavily on practitioner observation and patient self-reporting.

The 2025 case series published in the Journal of Contemporary Chiropractic is particularly notable because it paired subjective outcome measures with objective MRI imaging. Participants reported a 75% rate of positive subjective recovery for their condition and activities of daily living, and MRI measurements confirmed increased disc height and anterior-posterior disc dimension. When imaging confirms structural changes that align with clinical improvement, that combination strengthens the case that the therapy is producing mechanical effects rather than simply managing symptoms.

The University of South Florida's RESTORE study (NCT06525896), titled Research on Effectiveness of Non-Surgical Spinal Decompression Therapy and Outcomes With Radiographic Evaluation, is designed to build on this kind of evidence at a larger scale. The trial launched in January 2025 and has a primary completion date estimated for August 2026. Its inclusion of radiographic evaluation means it is specifically designed to assess whether structural changes occur, not just whether patients feel better. Results from this trial will add important data to the field.

Modern decompression equipment has also advanced considerably. Computer-controlled devices now incorporate sensor feedback that allows the system to adjust applied force in real time based on patient response, and therapy tracking software enables practitioners to individualize treatment parameters across sessions in ways that earlier equipment did not support. The technology gap between a generic traction table and a current decompression system is meaningful for both precision and outcome reproducibility.

PRP, BMAC, and Regenerative Biologics for Disc Tissue

Alongside decompression research, a growing body of clinical work is examining whether biological agents can stimulate actual regeneration of damaged disc tissue rather than simply relieving symptoms. A 2024 review in the Journal of Clinical Medicine, covering recent treatment strategies for lumbar disc herniation with a focus on non-surgical and regenerative approaches, found that PRP, BMAC, and LIPUS treatments have shown evidence of promoting tissue regeneration and alleviating symptoms in lumbar disc herniation cases across multiple clinical studies.

PRP therapy involves injecting a concentration of a patient's own platelets, which contain growth factors that play a role in tissue repair, directly into the affected disc. BMAC uses stem-cell-rich material drawn from bone marrow. LIPUS applies low-intensity sound waves to stimulate cellular repair activity. Each approach operates through a different biological mechanism, but all share the goal of encouraging disc tissue to repair rather than simply managing the inflammatory response that contributes to pain.

The regenerative field remains active and evolving. These therapies are not yet uniformly adopted as standard of care, and patient selection matters considerably. But the trajectory of the research points toward a future where the toolkit for disc herniation management includes biological options that address the underlying tissue damage rather than work around it. For patients exploring what non-surgical care looks like in 2026, understanding these options and discussing them with a qualified provider is a reasonable starting point.

At Las Vegas Spine and Disc, we stay current with the research so we can have genuinely informed conversations about what non-surgical care may offer you specifically. If you are managing disc pain or herniation symptoms and want to understand your options before committing to a course of action, we welcome you to book a consult. Every case is different, and the right path forward starts with a thorough evaluation.

6 Questions Patients Ask About Non-Surgical Disc Treatment in 2026

Patients navigating disc herniation decisions often arrive with similar questions. Here is what current research and clinical practice support.

  1. Does non-surgical decompression actually change anything structurally?: Recent case series data, including MRI measurements showing increased disc height and AP dimension following treatment, suggest that structural changes can occur. The RESTORE study, with a primary completion date of August 2026, is specifically designed to evaluate radiographic outcomes at scale.
  2. What makes PRP different from a standard cortisone injection?: Cortisone is an anti-inflammatory that reduces pain signals without targeting disc tissue repair. PRP uses growth factors from the patient's own blood to potentially stimulate actual tissue regeneration within the disc, addressing a different aspect of the underlying problem.
  3. How long does a course of non-surgical decompression typically take?: Treatment protocols vary by provider and patient presentation, but most structured programs involve multiple sessions over several weeks, with technology-assisted devices adjusting force parameters based on ongoing patient response data.
  4. Are these treatments appropriate for all disc herniation cases?: No. Patient selection is a critical variable in all non-surgical disc treatments. Factors including symptom severity, the specific level and type of herniation, prior treatment history, and overall health all influence whether a given approach is appropriate for an individual patient.
  5. What does BMAC bring that PRP does not?: BMAC draws stem-cell-rich material from bone marrow, which may provide a broader range of regenerative cellular signals compared to PRP's platelet-focused growth factor concentration. Both approaches are actively studied, and the clinical literature on each continues to grow.
  6. How does LIPUS fit into a regenerative disc treatment plan?: Low-intensity pulsed ultrasound delivers acoustic energy to stimulate cellular activity in disc tissue. It is typically used as part of a broader protocol rather than as a standalone treatment, and its effects are thought to complement biological injections by enhancing the cellular environment for repair.

Frequently Asked Questions

What is the RESTORE study and why does it matter?

The RESTORE study (NCT06525896) is a clinical trial at the University of South Florida examining whether non-surgical spinal decompression produces measurable radiographic changes, not just symptom improvement. It launched in January 2025 and has a primary completion date of August 2026. Its inclusion of imaging data makes it one of the more rigorous prospective studies in this field.

Is PRP therapy for disc herniation covered by insurance?

Coverage varies by insurer and plan. PRP and other regenerative biologics are often classified as investigational or elective by insurance carriers, meaning out-of-pocket costs are common. Discussing coverage specifics with your provider and insurer before beginning treatment is recommended.

Can non-surgical decompression eliminate the need for disc surgery?

For some patients, non-surgical decompression and other conservative approaches produce sufficient improvement that surgery is no longer necessary. For others, especially those with severe neurological compromise or cases that do not respond to conservative care, surgery may still be the appropriate path. This determination requires individual evaluation, not a general rule.

How do I know if I am a candidate for regenerative disc treatments?

Candidacy depends on several factors including the type and severity of herniation, symptom profile, imaging findings, and prior treatment response. A thorough clinical evaluation by a qualified spine care provider is the appropriate first step to assess whether these approaches fit your specific situation.